StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3036% above fair value
$461.26−4.19 (-0.90%)

Close on Nov 3, 2026Market cap $249.37BP/E 28.6Yield 2.09%

Amgen TEZSPIRE (tezepelumab-ekko by Quarter

TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%) (%)

QuarterlyAnnual

Amgen TEZSPIRE (tezepelumab-ekko: 42.0% in Q2 2026, down 4.0 pts from a year earlier.

Latest, Q2 2026
42.0%
Period ended Jun 30, 2026
Change on a year earlier
-4.0 pts
46.0% in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| TEZSPIRE ® | 486 | — | 486 | 342 | 42%”

Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗

Reported in Form 8-K Product Sales Detail by Product and Geographic Region.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202642.0%-4.0 ptsForm 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202620.0%-45.0 ptsForm 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 202560.0%-7.0 ptsForm 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202540.0%-27.0 ptsForm 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202546.0%-30.0 ptsForm 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 202565.0%-15.0 ptsForm 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 202467.0%–Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202467.0%–Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202476.0%–Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 202480.0%–Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗

Cite this data

StockData. (2026). Amgen TEZSPIRE (tezepelumab-ekko (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tezspire-yoy

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?